Page last updated: 2024-11-05

thalidomide and Atypical Lipomatous Tumor

thalidomide has been researched along with Atypical Lipomatous Tumor in 1 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, Y1
Xu, L1
Mayakonda, A1
Huang, ML1
Kanojia, D1
Tan, TZ1
Dakle, P1
Lin, RY1
Ke, XY1
Said, JW1
Chen, J1
Gery, S1
Ding, LW1
Jiang, YY1
Pang, A1
Puhaindran, ME1
Goh, BC1
Koeffler, HP1

Other Studies

1 other study available for thalidomide and Atypical Lipomatous Tumor

ArticleYear
Bromodomain and extraterminal proteins foster the core transcriptional regulatory programs and confer vulnerability in liposarcoma.
    Nature communications, 2019, 03-22, Volume: 10, Issue:1

    Topics: Animals; Azepines; Base Sequence; Carcinogenesis; Cell Line, Tumor; Enhancer Elements, Genetic; Geno

2019